Alkermes Plc (ALKS)
43.39
+0.94
(+2.21%)
USD |
NASDAQ |
Jun 09, 11:12
Alkermes SG&A Expense (Quarterly) : 264.60M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Amarin Corp. Plc | 19.35M |
| Prothena Corp. Plc | 12.67M |
| Catalyst Pharmaceuticals, Inc. | 43.52M |
| Inovio Pharmaceuticals, Inc. | 7.880M |
| Agios Pharmaceuticals, Inc. | 48.30M |